AIMS: Chronic hepatitis C alters the host's lipid metabolism and hepatitis C virus (HCV) eradication may be followed by an increase of serum cholesterol to adverse levels. We therefore aimed to determine the impact of chronic hepatitis C and its treatment on circulating lipids in a large European cohort of HCV genotype 1 patients. METHODS: The serum lipid profile of 575 HCV genotype 1-infected patients was characterized before, during and after treatment with pegylated interferon-α-2a (180 μg/week) and ribavirin (1000-1200 mg/day) for 48 weeks within a randomized controlled clinical trial. RESULTS:Total baseline cholesterol levels were significantly higher in patients with sustained virologic response (SVR) compared to nonresponders/relapsers (177 vs. 167 mg/dl, P=0.01), and low-cholesterol levels were an independent negative predictor of SVR (P=0.084). During the antiviral treatment, cholesterol levels substantially decreased as a putative marker of interferon-activity, but rebounded above baseline in patients with SVR (177-188 mg/dl, P=0.02), and to baseline in nonresponders/relapsers. Proportions of patients with cholesterol (>240 mg/dl) at baseline and after HCV eradication were 4 and 6%, respectively. Significant differences of triglyceride levels in patients with and without SVR were only observed at follow-up (136 and 117 mg/dl, respectively, P=0.028) but not at baseline. CONCLUSION: Our study reports a substantial pretreatment hypocholesterolemia in European HCV genotype 1 patients with nonresponse to interferon-α-based therapy and lower pretreatment cholesterol levels were an independent predictor of not attaining SVR. After treatment-induced HCV eradication median cholesterol levels increased above baseline, but the proportion of patients with high-risk cholesterol levels remained relatively low.
RCT Entities:
AIMS: Chronic hepatitis C alters the host's lipid metabolism and hepatitis C virus (HCV) eradication may be followed by an increase of serum cholesterol to adverse levels. We therefore aimed to determine the impact of chronic hepatitis C and its treatment on circulating lipids in a large European cohort of HCV genotype 1 patients. METHODS: The serum lipid profile of 575 HCV genotype 1-infectedpatients was characterized before, during and after treatment with pegylated interferon-α-2a (180 μg/week) and ribavirin (1000-1200 mg/day) for 48 weeks within a randomized controlled clinical trial. RESULTS: Total baseline cholesterol levels were significantly higher in patients with sustained virologic response (SVR) compared to nonresponders/relapsers (177 vs. 167 mg/dl, P=0.01), and low-cholesterol levels were an independent negative predictor of SVR (P=0.084). During the antiviral treatment, cholesterol levels substantially decreased as a putative marker of interferon-activity, but rebounded above baseline in patients with SVR (177-188 mg/dl, P=0.02), and to baseline in nonresponders/relapsers. Proportions of patients with cholesterol (>240 mg/dl) at baseline and after HCV eradication were 4 and 6%, respectively. Significant differences of triglyceride levels in patients with and without SVR were only observed at follow-up (136 and 117 mg/dl, respectively, P=0.028) but not at baseline. CONCLUSION: Our study reports a substantial pretreatment hypocholesterolemia in European HCV genotype 1 patients with nonresponse to interferon-α-based therapy and lower pretreatment cholesterol levels were an independent predictor of not attaining SVR. After treatment-induced HCV eradication median cholesterol levels increased above baseline, but the proportion of patients with high-risk cholesterol levels remained relatively low.
Authors: David A Sheridan; S H Bridge; M M E Crossey; D J Felmlee; H C Thomas; R D G Neely; S D Taylor-Robinson; M F Bassendine Journal: Metab Brain Dis Date: 2014-03-12 Impact factor: 3.584
Authors: Mostafa K El Awady; Noha G Bader El Din; Ashraf Tabll; Yaser El Hosary; Ashraf O Abdel Aziz; Hesham El Khayat; Mohsen Salama; Tawfeek H Abdelhafez Journal: World J Gastroenterol Date: 2013-01-14 Impact factor: 5.742
Authors: Adeel A Butt; Triin Umbleja; Janet W Andersen; Kenneth E Sherman; Raymond T Chung Journal: Clin Infect Dis Date: 2012-05-04 Impact factor: 9.079
Authors: Christian M Lange; Stephanie Bibert; Zoltan Kutalik; Philippe Burgisser; Andreas Cerny; Jean-Francois Dufour; Andreas Geier; Tilman J Gerlach; Markus H Heim; Raffaele Malinverni; Francesco Negro; Stephan Regenass; Klaus Badenhoop; Jörg Bojunga; Christoph Sarrazin; Stefan Zeuzem; Tobias Müller; Thomas Berg; Pierre-Yves Bochud; Darius Moradpour Journal: PLoS One Date: 2012-07-12 Impact factor: 3.240